{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:42Z","timestamp":1792790442811,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Qi-Yu Chi","award":["2021J0112"],"award-info":[{"award-number":["2021J0112"]}]},{"name":"Zhi-Bo Zhang","award":["2022J01691"],"award-info":[{"award-number":["2022J01691"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombosis (PVTT) has poor prognoses. This study evaluated the efficacy and safety of lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) and locoregional therapy (LRT) in uHCC patients with PVTT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Consecutive uHCC patients with PVTT who received LEN, PD-1, and LRT (LPLRT), such as transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), or TACE-HAIC, were analyzed. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs) were assessed. Subgroup analysis and multivariate Cox regression analysis was performed to identify independent risk factors for OS and PFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between January 2019 and December 2021, 74 uHCC patients with PVTT at four tertiary hospitals were enrolled. Of these, 38 were treated with LEN, PD-1, and TACE (LPT), 12 with LEN, PD-1, and HAIC (LPH), and 24 with LEN, PD-1, and TACE-HAIC (LPTH). According to the modified Response Evaluation Criteria in Solid Tumors, the ORR and DCR were 62.1% and 85.1%, respectively. The median OS was 23.3 months (95% CI, 18.9\u201327.7 months), and the median PFS was 13.2 months (95% CI, 8.8\u201317.6 months). Subgroup analyses revealed no significant differences in ORR, DCR, OS or PFS among the LPT, LPH, and LPTH groups. No grade 5 TRAEs occurred. Twenty-nine patients underwent salvage surgery. Significant differences in OS and PFS rates were observed between the resection and non-resection groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for both). Multivariate analysis showed that surgical resection was an independent prognostic factor for OS and PFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>LPLRT therapy offers a promising treatment for uHCC patients with PVTT, demonstrating high tumor response and conversion rates, prolonged survival, and manageable safety. Notably, for patients who remain eligible for surgery following LPLRT, salvage surgery is a safe, effective, and potentially prognostic treatment option.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14543-9","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:29:14Z","timestamp":1752154154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study"],"prefix":"10.1186","volume":"25","author":[{"given":"Qi-Yu","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Di","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hui","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Geng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"3","key":"14543_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"14543_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"14543_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"24","key":"14543_CR4","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","volume":"37","author":"X Wei","year":"2019","unstructured":"Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol. 2019;37(24):2141\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"14543_CR5","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/hep.30490","volume":"69","author":"XP Zhang","year":"2019","unstructured":"Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, et al. An Eastern hepatobiliary surgery hospital\/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology. 2019;69(5):2076\u201390.","journal-title":"Hepatology"},{"issue":"8","key":"14543_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ejso.2019.03.042","volume":"45","author":"X Xiang","year":"2019","unstructured":"Xiang X, Lau WY, Wu ZY, Zhao C, Ma YL, Xiang BD, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. Eur J Surg Oncol. 2019;45(8):1460\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"14543_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s00330-016-4445-9","volume":"27","author":"B Gorodetski","year":"2017","unstructured":"Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27(2):526\u201335.","journal-title":"Eur Radiol"},{"issue":"12","key":"14543_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.120.242933","volume":"61","author":"M Venerito","year":"2020","unstructured":"Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, et al. NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radiation therapy with (90)Y resin microspheres versus Sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61(12):1736\u201342.","journal-title":"J Nucl Med"},{"key":"14543_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/JHC.S276528","volume":"7","author":"S Han","year":"2020","unstructured":"Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, et al. Appraisal of Long-Term outcomes of Liver-Directed concurrent chemoradiotherapy for hepatocellular carcinoma with major portal vein invasion. J Hepatocellular Carcinoma. 2020;7:403\u201312.","journal-title":"J Hepatocellular Carcinoma"},{"issue":"2","key":"14543_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","volume":"18","author":"J Luo","year":"2011","unstructured":"Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413\u201320.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"14543_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"14543_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109(5):1222\u201330.","journal-title":"Int J Surg"},{"key":"14543_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac114","author":"WF Qu","year":"2022","unstructured":"Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022. https:\/\/doi.org\/10.1093\/bjsopen\/zrac114.","journal-title":"BJS Open"},{"key":"14543_CR14","first-page":"102367","volume":"67","author":"XK Wu","year":"2024","unstructured":"Wu XK, Yang LF, Chen YF, Chen ZW, Lu H, Shen XY, et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinMed. 2024;67:102367.","journal-title":"EClinMed"},{"key":"14543_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/JHC.S332420","volume":"8","author":"JY Wu","year":"2021","unstructured":"Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, et al. Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A multicenter retrospective study. J Hepatocellular Carcinoma. 2021;8:1233\u201340.","journal-title":"J Hepatocellular Carcinoma"},{"issue":"3","key":"14543_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000528356","volume":"12","author":"JY Wu","year":"2023","unstructured":"Wu JY, Zhang ZB, Zhou JY, Ke JP, Bai YN, Chen YF, et al. Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study. Liver Cancer. 2023;12(3):229\u201337.","journal-title":"Liver Cancer"},{"issue":"20","key":"14543_CR17","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/cncr.33677","volume":"127","author":"X Ding","year":"2021","unstructured":"Ding X, Sun W, Li W, Shen Y, Guo X, Teng Y, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study. Cancer. 2021;127(20):3782\u201393.","journal-title":"Cancer"},{"issue":"17","key":"14543_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2217\/imt-2021-0192","volume":"13","author":"BJ Liu","year":"2021","unstructured":"Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395\u2013405.","journal-title":"Immunotherapy"},{"issue":"3","key":"14543_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"10126","key":"14543_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"20","key":"14543_CR21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"4","key":"14543_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000523997","volume":"11","author":"J Sun","year":"2022","unstructured":"Sun J, Guo R, Bi X, Wu M, Tang Z, Lau WY, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition). Liver Cancer. 2022;11(4):315\u201328.","journal-title":"Liver Cancer"},{"issue":"11","key":"14543_CR23","first-page":"5455","volume":"13","author":"Z Lin","year":"2023","unstructured":"Lin Z, Chen D, Hu X, Huang D, Chen Y, Zhang J, et al. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and Arterioportal fistulas. Am J Cancer Res. 2023;13(11):5455\u201365.","journal-title":"Am J Cancer Res"},{"key":"14543_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377.","journal-title":"Eur J Cancer"},{"key":"14543_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae032","author":"L Wang","year":"2024","unstructured":"Wang L, Feng JK, Lu CD, Wu JY, Zhou B, Wang K, et al. Salvage surgery for initially unresectable HCC with PVTT converted by locoregional treatment plus tyrosine kinase inhibitor and anti-PD-1 antibody. Oncologist. 2024. https:\/\/doi.org\/10.1093\/oncolo\/oyae032.","journal-title":"Oncologist"},{"issue":"3","key":"14543_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339\u201364.","journal-title":"Dig Dis"},{"key":"14543_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923566","volume":"12","author":"C He","year":"2022","unstructured":"He C, Ge N, Wang X, Li H, Chen S, Yang Y. Conversion therapy of large unresectable hepatocellular carcinoma with ipsilateral portal vein tumor thrombus using portal vein embolization plus transcatheter arterial chemoembolization. Front Oncol. 2022;12: 923566.","journal-title":"Front Oncol"},{"issue":"32","key":"14543_CR28","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.3748\/wjg.v22.i32.7289","volume":"22","author":"SL Chan","year":"2016","unstructured":"Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22(32):7289\u2013300.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"14543_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"14543_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1148\/radiol.10101058","volume":"258","author":"GE Chung","year":"2011","unstructured":"Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258(2):627\u201334.","journal-title":"Radiology"},{"issue":"12","key":"14543_CR31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3109\/00365520903367262","volume":"44","author":"JR Eun","year":"2009","unstructured":"Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009;44(12):1477\u201386.","journal-title":"Scand J Gastroenterol"},{"key":"14543_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijsu.2017.06.082","volume":"44","author":"M Hamaoka","year":"2017","unstructured":"Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study. Int J Surg. 2017;44:223\u20138.","journal-title":"Int J Surg"},{"key":"14543_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-230X-14-84","volume":"14","author":"T Nakazawa","year":"2014","unstructured":"Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to Sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"14543_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1148\/radiol.14131946","volume":"272","author":"K Zhu","year":"2014","unstructured":"Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2013a retrospective controlled study. Radiology. 2014;272(1):284\u201393.","journal-title":"Radiology"},{"issue":"1","key":"14543_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12072-015-9673-6","volume":"10","author":"J Long","year":"2016","unstructured":"Long J, Zheng JS, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int. 2016;10(1):175\u201384.","journal-title":"Hepatol Int"},{"key":"14543_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578633","volume":"10","author":"X Ding","year":"2020","unstructured":"Ding X, Sun W, Chen J, Li W, Shen Y, Guo X, et al. Percutaneous radiofrequency ablation combined with transarterial chemoembolization plus Sorafenib for large hepatocellular carcinoma invading the portal venous system: a prospective randomized study. Front Oncol. 2020;10: 578633.","journal-title":"Front Oncol"},{"issue":"6","key":"14543_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682\u2013720.","journal-title":"Liver Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14543-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14543-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:36:39Z","timestamp":1757219799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14543-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14543"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14543-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the World Medical Association Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital of Fujian Medical University (Approval Number: 2024\u2009\u2212\u2009587). All participants provided informed consent. Ethical standards outlined in the Declaration of Helsinki were rigorously upheld, ensuring the protection of patient privacy and confidentiality throughout the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1162"}}